GlycopeptidesBrands: Vancocin

Vancomycin

Vancomycin Hydrochloride — Glycopeptide Antibiotic

💡 ICU High-Yield Summary: Parenteral glycopeptide for serious susceptible Gram-positive infections, especially MRSA; in serious invasive MRSA, use an appropriate loading strategy when rapid exposure is needed and AUC-guided monitoring (target AUC24/MIC 400–600 when MIC is assumed 1 mg/L) rather than routine trough-only 15–20 mg/L targeting.

🦠 Compare this agent in the Antimicrobial Pharmacology & Stewardship MasterclassOpen →

🧬 Mechanism of Action & Target Pathway

Cell Wall Peptidoglycan D-Ala-D-Ala Binding

Binds with high affinity to the D-alanyl-D-alanine terminus of cell wall peptidoglycan precursors.
Sterically inhibits transglycosylation and transpeptidation, halting peptidoglycan polymer elongation.
Alters bacterial cell membrane permeability and impairs RNA synthesis.
Produces slow bactericidal cell death against Gram-positive bacteria.

Vancomycin → D-Ala-D-Ala Binding → Steric Transglycosylation Blockade → Cell Wall Synthesis Stop

Antimicrobial Spectrum & Coverage Framework — Vancomycin

Educational Reference

Gram-Positive Organisms

Covered:

✓ Methicillin-resistant Staphylococcus aureus (MRSA)
✓ Methicillin-susceptible Staphylococcus aureus (MSSA)
✓ Coagulase-negative Staphylococci (CoNS)
✓ Streptococcus pneumoniae (penicillin-resistant)
✓ Enterococcus faecalis (vancomycin-susceptible)
✓ Clostridioides difficile (ORAL route only)

Not Covered:

✕ Vancomycin-resistant Enterococcus (VRE faecium vanA/vanB)
✕ VRSA
✕ VISA (relative resistance)

Gram-Negative Organisms

Covered:

Not Covered:

✕ All Gram-negative bacteria (Large molecular weight prevents penetration through outer membrane porins)

Anaerobes & Special Pathogens

Covered:

✓ Clostridium perfringens
✓ Peptostreptococcus spp.
✓ Clostridioides difficile (ORAL route only)

Not Covered:

✕ Bacteroides fragilis
✕ Gram-negative anaerobes

High-Yield Exam & Clinical Gaps

⚠️ All Gram-negative Bacilli (E. coli, Pseudomonas)⚠️ VRE (vanA/vanB)⚠️ Oral Vancomycin is NOT absorbed systemically

Pharmacokinetics & Pharmacodynamics (PK/PD) — Vancomycin

auc mic

Target ParameterAUC24 / MIC ratio (Target AUC24/MIC = 400–600 mg·h/L for MRSA assuming MIC ≤ 1 mg/L)

Half-Life (t1/2)4.0 to 6.0 hours in normal renal function (extended to 60–120 hours in ESRD)

Protein Binding30% to 55%

Primary Elimination75% to 90% renal excretion via glomerular filtration

Metabolism Pathway:Minimal hepatic metabolism

Volume of Distribution Notes:0.4 to 1.0 L/kg (actual body weight used for loading dose calculations)

⚖️ ICU Clinical Reasoning

Why I Choose It (Indications & Strengths)

✓A standard empiric anti-MRSA option when the syndrome and local epidemiology warrant MRSA coverage (for example selected HAP/VAP, severe sepsis with MRSA risk, purulent/NSTI syndromes, or suspected catheter-related infection).
✓Important oral therapy for Clostridioides difficile infection: vancomycin is an acceptable alternative to fidaxomicin for many initial/non-fulminant episodes and remains the backbone of fulminant CDI therapy at higher enteral dosing; oral vancomycin has minimal systemic absorption in most patients.
✓Well-established therapeutic drug monitoring (TDM) protocols based on Bayesian AUC estimation.

Why I Don't (Limitations & Gaps)

✕Nephrotoxicity risk rises with excessive vancomycin exposure (especially AUC above the recommended range), duration, critical illness and other nephrotoxic exposures. Observational studies linked vancomycin plus piperacillin–tazobactam to more creatinine-defined AKI, but ACORN did not show more AKI/death versus cefepime.
✕Infusion-related Vancomycin Flushing Syndrome ('Red Man Syndrome') if infused too rapidly (<1 hour per 1000 mg).
✕For definitive MSSA bacteremia, an anti-staphylococcal beta-lactam (such as cefazolin or nafcillin/oxacillin) is generally preferred when tolerated; observational data associate definitive vancomycin therapy with worse outcomes than beta-lactams.

⭐ Bedside Pearl: For serious suspected/confirmed MRSA infection in a critically ill patient, use an actual-body-weight loading strategy when rapid target attainment is needed (2020 consensus: commonly 20–35 mg/kg, maximum 3 g) and transition to AUC-guided dosing (target AUC24/MIC 400–600 when MIC is assumed 1 mg/L). AUC-guided monitoring reduces excessive exposure/nephrotoxicity risk compared with trough-only targeting, but do not promise a fixed '50% AKI reduction.'

💉 Dosing & Administration Protocols

Routine ICU Dosing

Serious MRSA infection: consider an actual-body-weight loading dose (commonly 20–35 mg/kg in critically ill adults; max 3000 mg), then individualize maintenance dosing using renal function and preferably Bayesian/AUC-guided monitoring rather than a fixed q8–12h regimen for every ICU patient.

Syndrome-Specific Regimens

Severe MRSA Infection / HAP / VAP / Septic Shock2020 ASHP/IDSA/SIDP Therapeutic Monitoring Guidelines for Vancomycin (Rybak MJ et al. Am J Health-Syst Pharm 2020;77:835-864).

For critically ill adults with serious MRSA infection, a loading dose within the 2020 consensus range (20–35 mg/kg actual body weight; max 3 g) may be used when rapid target attainment is needed. Maintenance dose/interval should be individualized to renal function and measured AUC rather than fixed q8–12h dosing.

Clostridioides difficile Colitis (Oral Route ONLY)IDSA/SHEA 2021 C. difficile Guidelines (Johnson S et al. Clin Infect Dis 2021;73:e1029).

Non-fulminant CDI: vancomycin 125 mg PO q6h for 10 days is an acceptable regimen (fidaxomicin is preferred when feasible in the 2021 IDSA/SHEA focused update). Fulminant CDI: vancomycin 500 mg enterally q6h plus IV metronidazole, with rectal vancomycin considered if ileus is present.

Renal dosing standard: Use the renal-function metric specified by the cited drug source (often Cockcroft–Gault CrCl for labeling). KDIGO AKI stage describes AKI severity, not drug clearance, and should not be converted directly into a dose. In rapidly changing AKI or RRT, integrate creatinine trend/urine output, TDM when available, and the actual IHD/CRRT prescription (including effluent rate when relevant).

Renal Function Dosing

CrCl Range	Dose Adjustment
Stable renal function	Choose an initial weight- and renal-function–based maintenance regimen, then individualize to measured AUC24/MIC 400–600 for serious MRSA. Fixed CrCl-to-q8/q12/q24 tables are starting estimates, not definitive ICU dosing.
AKI / rapidly changing renal function	Do not rely on a static creatinine-clearance interval table. Give an appropriate loading dose when rapid exposure is needed, obtain early concentrations/AUC, and redose according to changing clearance, renal-replacement modality and clinical trajectory.
Severe renal impairment without dialysis	Use extended/intermittent maintenance dosing guided by measured concentrations/AUC and serial renal function; avoid an automatic 'redose at trough 15–20 mg/L' rule for all patients.

Dialytic Clearance (HD / CRRT)

Intermittent Hemodialysis (HD):Use a dialysis-specific protocol that accounts for high-flux membrane, timing relative to dialysis and residual kidney function. The 2020 consensus uses predialysis concentrations of about 15–20 mg/L as a practical surrogate likely to achieve AUC 400–600 when MIC is 1 mg/L; actual post-HD dose and timing require TDM rather than a universal 10–15 mg/kg rule.

Continuous Renal Replacement (CRRT):At conventional CRRT effluent rates around 20–25 mL/kg/h, the 2020 consensus suggests a 20–25 mg/kg actual-body-weight load and an initial maintenance range of 7.5–10 mg/kg q12h, followed by serum concentration/AUC-guided adjustment within the first 24 hours. Higher/lower effluent rates, interruptions, filter performance, residual renal function and changing volume status can materially alter clearance—do not use one fixed CRRT regimen.

🩺 Organ Failure Considerations

Renal Failure & AKI

Primary renal elimination. Glomerular filtration dysfunction causes rapid accumulation. High AUC24 (>600 mg·h/L) directly induces renal tubular cell injury and apoptosis.

Hepatic Impairment & Cirrhosis

No dose reduction required for isolated liver dysfunction.

⚠️ Toxicity & Safety Warnings

Major Warnings

🚨Nephrotoxicity: risk increases as exposure rises, particularly above the recommended AUC range; avoid presenting a trough threshold or piperacillin–tazobactam combination as a deterministic cause in every patient.
🚨Vancomycin Flushing Syndrome (Red Man Syndrome): Non-immunologic histamine release triggered by rapid IV infusion rates.
🚨Ototoxicity: Auditory nerve damage (rare, typically associated with extreme overdose or concurrent aminoglycosides).

🔄 Bedside Drug Interactions

Interacting Drug	Mechanism	Clinical Consequence	Mandatory ICU Action
Piperacillin-Tazobactam (Zosyn)	Observed association with creatinine-defined AKI in many nonrandomized studies; mechanism and causal contribution remain debated	Many observational cohorts report more creatinine-defined AKI with vancomycin + piperacillin–tazobactam, but randomized ACORN data did not show a significant difference in the composite of AKI or death versus cefepime.	Monitor renal function and antimicrobial indication. Do not automatically switch piperacillin–tazobactam to cefepime solely to prevent AKI; ACORN found no significant AKI/death difference and more neurologic dysfunction with cefepime.
Aminoglycosides / Loop Diuretics	Additive nephrotoxic and ototoxic damage	Increased risk of renal failure and hearing loss	Monitor renal function closely and perform vancomycin TDM at a frequency appropriate to illness severity, renal stability and treatment duration; daily AUC estimation is not required for every stable patient.

📊 Monitoring & TDM Protocols

Required Monitoring Parameters

▪ Therapeutic Drug Monitoring (TDM): Target AUC24/MIC 400–600 mg·h/L using Bayesian software or 2-point peak/trough levels
▪ If AUC monitoring is unavailable, use an institutionally validated concentration-based strategy; the 2020 consensus moved away from routine trough-only 15–20 mg/L targeting for serious MRSA because it can drive excessive exposure/nephrotoxicity.
▪ Serum Creatinine and BUN daily
▪ IV infusion: administer sufficiently slowly to reduce infusion reactions; commonly at least 60 minutes and no faster than about 10–15 mg/min, with longer infusions for larger doses or prior infusion reactions per local policy.

Therapeutic Drug Monitoring (TDM) Protocol

Target Trough:Trough-only 15–20 mg/L is no longer the preferred general target for serious MRSA; hemodialysis is a special case where predialysis 15–20 mg/L is used pragmatically to approximate AUC 400–600.

Target AUC24/MIC:400–600 mg·h/L (assuming MRSA MIC ≤ 1 mg/L)

Sampling Timing:For serious MRSA, obtain AUC-relevant concentrations early—generally within the first 24–48 hours, and earlier/more often when renal function is unstable or renal replacement therapy changes. Do not wait automatically for a 4th/5th-dose steady-state trough.

Antimicrobial Stewardship — Broader ≠ Better (Vancomycin)

🌱 De-Escalation & Narrowing Principle:

A negative nasal MRSA PCR can strongly support de-escalation of empiric vancomycin for pneumonia when local test performance and pretest probability are appropriate; do not make it an automatic rule in every syndrome. If cultures confirm MSSA, use a preferred anti-staphylococcal beta-lactam when tolerated.

🛡️ "Broader ≠ Better" Bedside Teaching Point:

For definitive MSSA bacteremia, cefazolin or an anti-staphylococcal penicillin is preferred when tolerated. Vancomycin should generally be reserved for patients who cannot receive an appropriate beta-lactam rather than being continued simply because it was started empirically.

Evidence Status

Current

Last Medically Reviewed

2026-08-28

Evidence Checked Through

2026-08-28

Notes: Targeted claim-level release audit completed on 2026-08-28. Dosing, renal/HD/CRRT language, contraindications, major warnings, and preferred-therapy claims were reconciled against current guideline/consensus or regulator-approved prescribing information where applicable; unsupported extrapolations were removed or qualified.

📚 Evidence Traceability & Guideline Citations

"2020 ASHP/IDSA/SIDP Consensus Guidelines recommend AUC24/MIC 400–600 mg·h/L over trough-only monitoring to reduce AKI."

Source: Therapeutic monitoring of vancomycin in adult patients: A consensus guideline by ASHP, IDSA, PIDS, SIDP. Am J Health-Syst Pharm 2020;77(11):835-864.View Reference ↗

"For critically ill adults with serious MRSA infection, the 2020 consensus allows actual-body-weight loading doses of 20–35 mg/kg (maximum 3 g) when rapid target attainment is needed."

Source: Rybak MJ, et al. 2020 ASHP/IDSA/PIDS/SIDP vancomycin therapeutic-monitoring consensus guideline. Am J Health-Syst Pharm. 2020;77:835-864.View Reference ↗

🩺 Bedside Patient Scenarios

Empiric Loading Dose in Septic Shock

Scenario: A 90 kg male presents in septic shock from severe MRSA pneumonia.

Bedside Decision: Give an appropriate actual-body-weight loading dose (for 90 kg, a dose in the consensus 20–35 mg/kg range can be selected, maximum 3 g) when rapid MRSA exposure is needed; choose maintenance only after considering renal function and an AUC-guided plan rather than automatically prescribing 1500 mg q12h.

Rationale: Critical illness can expand volume of distribution, making a loading dose useful for rapid target attainment. Maintenance exposure—not the loading dose alone—should then be individualized to AUC and changing renal function.

De-Escalation in Confirmed MSSA Bacteremia

Scenario: Blood cultures grow Staphylococcus aureus identified as MSSA (oxacillin susceptible).

Bedside Decision: Discontinue Vancomycin and start Cefazolin 2.0 g IV every 8 hours.

Rationale: Beta-lactams (Cefazolin/Nafcillin) demonstrate lower mortality and faster bacterial clearance than Vancomycin for MSSA.

🎯 Exam Traps & Board Misconceptions

❌ Misconception:"IV Vancomycin treats Clostridioides difficile colitis."

✓ Reality: FALSE. IV vancomycin does not achieve reliable therapeutic intraluminal colonic concentrations and is not an accepted treatment for C. difficile infection; oral/enteral (and selected rectal) vancomycin delivers drug to the gut lumen.

Oral/enteral vancomycin is poorly absorbed and produces high intraluminal colonic concentrations for C. difficile infection. IV vancomycin is used for systemic infections and does not provide reliable therapeutic colonic luminal exposure for CDI.

Continue Learning

Topic

Ventilator-Associated Pneumonia (VAP)

Quantitative lower tract sampling (ETA vs BAL), rapid multiplex PCR panels and stewardship interpretation, PK/PD extended beta-lactams, 7-day duration, and the SHEA prevention bundle.

View detail

Topic

Hospital-Acquired Pneumonia (HAP)

Nosocomial pneumonia developing ≥ 48 hours after admission in non-ventilated patients, host and antibiogram MDR risk tailoring, nasal MRSA PCR screening, and 7-day de-escalation.

View detail

Clinical Case

Ventilator-Associated Pneumonia Due to DTR Pseudomonas

Susceptibility-directed treatment with newer antipseudomonal beta-lactams

View detail

Clinical Case

Invasive Candidemia in the Critically Ill

Early echinocandin therapy, source control, clearance cultures, and selective metastatic-focus evaluation

View detail

Problem

New Tachycardia & Tachyarrhythmias

Algorithmic triage of acute heart rates > 100–150 bpm: stability screen (immediate cardioversion if unstable), narrow vs wide QRS differentiation, Brugada VT rules, and sinus tachycardia etiology search.

View detail

Problem

Acute Altered Mental Status & ICU Delirium

Systematic neurologic evaluation: immediate metabolic/toxic screening (glucose, hypoxia, hypercapnia), nonconvulsive status epilepticus exclusion, structural CT triage, and CAM-ICU delirium management.

View detail